The aim of this study was to analyze the influence of SOST (sclerostin), PTH (parathyroid hormone), FGF2 (fibroblast growth factor 2), FDPS (farnesyl diphosphate synthase), GGPS1 (geranylgeranyl diphosphate synthase), and LRP5 (low density lipoprotein receptor-related protein 5) gene variants on the response to treatment with BPs. This evidence concerns the gene LRP5 and Bartsocas-Papas syndrome 1.